Yappie830
2021-10-11
Like n share please
ChemoCentryx shares surged 8% in morning trading<blockquote>ChemoCentryx股价早盘飙升8%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":826049298,"tweetId":"826049298","gmtCreate":1633960985769,"gmtModify":1633960985931,"author":{"id":3582890719532983,"idStr":"3582890719532983","authorId":3582890719532983,"authorIdStr":"3582890719532983","name":"Yappie830","avatar":"https://static.tigerbbs.com/20b85051cf2f72ca21360c0cd39b3db1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like n share please </p></body></html>","htmlText":"<html><head></head><body><p>Like n share please </p></body></html>","text":"Like n share please","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/826049298","repostId":1145882261,"repostType":4,"repost":{"id":"1145882261","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633960460,"share":"https://www.laohu8.com/m/news/1145882261?lang=zh_CN&edition=full","pubTime":"2021-10-11 21:54","market":"us","language":"en","title":"ChemoCentryx shares surged 8% in morning trading<blockquote>ChemoCentryx股价早盘飙升8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1145882261","media":"Tiger Newspress","summary":"ChemoCentryx surged 8% in morning trading after the stock Popped 96% last trading day.\n\nChemoCentryx","content":"<p>ChemoCentryx surged 8% in morning trading after the stock Popped 96% last trading day.</p><p><blockquote>ChemoCentryx在上个交易日上涨96%后，早盘交易中飙升8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/afb4a9abcf94c818cf9f9031dbe942e9\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> ChemoCentryx, Inc. announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug development experience leading multiple global programs across early and late stages of development.</p><p><blockquote>ChemoCentryx，Inc.宣布任命医学博士Rita I.Jain为执行副总裁兼首席医疗官。在此职位上，她将监督开发活动，包括临床开发、开发运营、监管事务以及药物安全和药物警戒。Jain博士将继续在ChemoCentryx董事会任职（她自2019年3月起担任该董事会），担任执行员工董事。Jain博士是一名委员会认证的风湿病学家，拥有20多年的药物开发经验，领导了多个早期和晚期开发阶段的全球项目。</blockquote></p><p> \"Today we bolster our strength as an organization - and across a range of extremely important therapeutic areas - by bringing Rita Jain to the ChemoCentryx leadership team,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We welcome her; we cite her impressive track record in drug development with years of experience in leading highly innovative programs. All of these qualities, combined with her dedication to making a fundamental difference in patients’ lives, are a perfect complement to our ChemoCentryx mission.”</p><p><blockquote>ChemoCentryx总裁兼首席执行官Thomas J.Schall博士说：“今天，我们通过将Rita Jain引入ChemoCentryx领导团队，增强了我们作为一个组织的实力——以及在一系列极其重要的治疗领域。我们欢迎她；我们引用了她在药物开发方面令人印象深刻的记录以及多年领导高度创新项目的经验。所有这些品质，加上她致力于从根本上改变患者生活的奉献精神，是对我们ChemoCentryx使命的完美补充。”</blockquote></p><p> “Through my role on ChemoCentryx’s Board of Directors I’ve seen firsthand the value of the science and promise of the company’s pipeline. I’m excited to now join the leadership team and play a larger role in driving these assets forward, particularly at such a transformational time,” said Dr. Jain. “I am impressed with the company’s successful execution to date and look forward to supporting its future achievements.”</p><p><blockquote>“通过我在ChemoCentryx董事会的角色，我亲眼目睹了科学的价值和公司管道的前景。我很高兴现在加入领导团队，并在推动这些资产向前发展方面发挥更大的作用，特别是在这样一个转型时期，”贾恩博士说。“我对公司迄今为止的成功执行印象深刻，并期待支持其未来的成就。”</blockquote></p><p> Dr Jain previously served as Chief Medical officer ofImmunovant, Inc.and prior to that Senior Vice President and Chief Medical Officer ofAkebia Therapeutics, Inc.Before joining Akebia, Dr. Jain was Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc., and prior to that served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa®and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others.</p><p><blockquote>Jain博士曾担任Immunovant，Inc.的首席医疗官，在此之前，他是Fakebia Therapeutics，Inc.的高级副总裁兼首席医疗官。在加入Akebia之前，Jain博士是AbbVie，Inc.的男性和女性健康和代谢发展副总裁，在此之前，他曾担任各种领导职务，包括Abbott Laboratories的部门副总裁。Jain博士领导了多个后期项目的设计和执行，包括Orilissa®还有奥里亚恩。®她还领导了一系列不同治疗领域的项目，包括炎症、疼痛、免疫学和肾病学等。</blockquote></p><p> Before Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle (acquired by Pharmacia and subsequently Pfizer). Earlier in her career, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.</p><p><blockquote>在加入雅培之前，她曾在G.D.关节炎、炎症和疼痛部门担任管理职务。塞尔（被法玛西亚收购，随后被辉瑞收购）。在她职业生涯的早期，Jain博士是纽约北岸大学医院的一名教员，并被任命为纽约大学医学院的医学助理教授。</blockquote></p><p> Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.</p><p><blockquote>贾恩博士获得了刘/C.W的生物学学士学位。波斯特和她在纽约州立大学石溪医学院的医学博士学位。Jain博士在斯塔滕岛大学医院完成了内科医学培训，随后在北岸大学医院获得了风湿病学奖学金，并在达拉斯的德克萨斯大学西南医学中心获得了临床研究奖学金。</blockquote></p><p> <b>About ChemoCentryx</b></p><p><blockquote><b>关于ChemoCentryx</b></blockquote></p><p> ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.</p><p><blockquote>ChemoCentryx是一家生物制药公司，致力于商业化和开发治疗炎症和自身免疫性疾病和癌症的新药。ChemoCentryx针对趋化因子和化学引诱剂系统来发现、开发和商业化口服疗法。在美国，ChemoCentryx销售TAVNEOS™（avacopan），首个被批准作为严重活动性ANCA相关血管炎成人患者辅助治疗的口服补体5a受体抑制剂。TAVNEOS还处于后期临床开发阶段，用于治疗严重化脓性汗腺炎和C3肾小球病（C3G）。此外，ChemoCentryx还拥有针对其他炎症和自身免疫性疾病以及癌症中化学引诱受体的早期候选药物。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChemoCentryx shares surged 8% in morning trading<blockquote>ChemoCentryx股价早盘飙升8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemoCentryx shares surged 8% in morning trading<blockquote>ChemoCentryx股价早盘飙升8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-11 21:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ChemoCentryx surged 8% in morning trading after the stock Popped 96% last trading day.</p><p><blockquote>ChemoCentryx在上个交易日上涨96%后，早盘交易中飙升8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/afb4a9abcf94c818cf9f9031dbe942e9\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> ChemoCentryx, Inc. announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug development experience leading multiple global programs across early and late stages of development.</p><p><blockquote>ChemoCentryx，Inc.宣布任命医学博士Rita I.Jain为执行副总裁兼首席医疗官。在此职位上，她将监督开发活动，包括临床开发、开发运营、监管事务以及药物安全和药物警戒。Jain博士将继续在ChemoCentryx董事会任职（她自2019年3月起担任该董事会），担任执行员工董事。Jain博士是一名委员会认证的风湿病学家，拥有20多年的药物开发经验，领导了多个早期和晚期开发阶段的全球项目。</blockquote></p><p> \"Today we bolster our strength as an organization - and across a range of extremely important therapeutic areas - by bringing Rita Jain to the ChemoCentryx leadership team,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We welcome her; we cite her impressive track record in drug development with years of experience in leading highly innovative programs. All of these qualities, combined with her dedication to making a fundamental difference in patients’ lives, are a perfect complement to our ChemoCentryx mission.”</p><p><blockquote>ChemoCentryx总裁兼首席执行官Thomas J.Schall博士说：“今天，我们通过将Rita Jain引入ChemoCentryx领导团队，增强了我们作为一个组织的实力——以及在一系列极其重要的治疗领域。我们欢迎她；我们引用了她在药物开发方面令人印象深刻的记录以及多年领导高度创新项目的经验。所有这些品质，加上她致力于从根本上改变患者生活的奉献精神，是对我们ChemoCentryx使命的完美补充。”</blockquote></p><p> “Through my role on ChemoCentryx’s Board of Directors I’ve seen firsthand the value of the science and promise of the company’s pipeline. I’m excited to now join the leadership team and play a larger role in driving these assets forward, particularly at such a transformational time,” said Dr. Jain. “I am impressed with the company’s successful execution to date and look forward to supporting its future achievements.”</p><p><blockquote>“通过我在ChemoCentryx董事会的角色，我亲眼目睹了科学的价值和公司管道的前景。我很高兴现在加入领导团队，并在推动这些资产向前发展方面发挥更大的作用，特别是在这样一个转型时期，”贾恩博士说。“我对公司迄今为止的成功执行印象深刻，并期待支持其未来的成就。”</blockquote></p><p> Dr Jain previously served as Chief Medical officer ofImmunovant, Inc.and prior to that Senior Vice President and Chief Medical Officer ofAkebia Therapeutics, Inc.Before joining Akebia, Dr. Jain was Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc., and prior to that served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa®and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others.</p><p><blockquote>Jain博士曾担任Immunovant，Inc.的首席医疗官，在此之前，他是Fakebia Therapeutics，Inc.的高级副总裁兼首席医疗官。在加入Akebia之前，Jain博士是AbbVie，Inc.的男性和女性健康和代谢发展副总裁，在此之前，他曾担任各种领导职务，包括Abbott Laboratories的部门副总裁。Jain博士领导了多个后期项目的设计和执行，包括Orilissa®还有奥里亚恩。®她还领导了一系列不同治疗领域的项目，包括炎症、疼痛、免疫学和肾病学等。</blockquote></p><p> Before Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle (acquired by Pharmacia and subsequently Pfizer). Earlier in her career, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.</p><p><blockquote>在加入雅培之前，她曾在G.D.关节炎、炎症和疼痛部门担任管理职务。塞尔（被法玛西亚收购，随后被辉瑞收购）。在她职业生涯的早期，Jain博士是纽约北岸大学医院的一名教员，并被任命为纽约大学医学院的医学助理教授。</blockquote></p><p> Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.</p><p><blockquote>贾恩博士获得了刘/C.W的生物学学士学位。波斯特和她在纽约州立大学石溪医学院的医学博士学位。Jain博士在斯塔滕岛大学医院完成了内科医学培训，随后在北岸大学医院获得了风湿病学奖学金，并在达拉斯的德克萨斯大学西南医学中心获得了临床研究奖学金。</blockquote></p><p> <b>About ChemoCentryx</b></p><p><blockquote><b>关于ChemoCentryx</b></blockquote></p><p> ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.</p><p><blockquote>ChemoCentryx是一家生物制药公司，致力于商业化和开发治疗炎症和自身免疫性疾病和癌症的新药。ChemoCentryx针对趋化因子和化学引诱剂系统来发现、开发和商业化口服疗法。在美国，ChemoCentryx销售TAVNEOS™（avacopan），首个被批准作为严重活动性ANCA相关血管炎成人患者辅助治疗的口服补体5a受体抑制剂。TAVNEOS还处于后期临床开发阶段，用于治疗严重化脓性汗腺炎和C3肾小球病（C3G）。此外，ChemoCentryx还拥有针对其他炎症和自身免疫性疾病以及癌症中化学引诱受体的早期候选药物。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCXI":"ChemoCentryx"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145882261","content_text":"ChemoCentryx surged 8% in morning trading after the stock Popped 96% last trading day.\n\nChemoCentryx, Inc. announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug development experience leading multiple global programs across early and late stages of development.\n\"Today we bolster our strength as an organization - and across a range of extremely important therapeutic areas - by bringing Rita Jain to the ChemoCentryx leadership team,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We welcome her; we cite her impressive track record in drug development with years of experience in leading highly innovative programs. All of these qualities, combined with her dedication to making a fundamental difference in patients’ lives, are a perfect complement to our ChemoCentryx mission.”\n“Through my role on ChemoCentryx’s Board of Directors I’ve seen firsthand the value of the science and promise of the company’s pipeline. I’m excited to now join the leadership team and play a larger role in driving these assets forward, particularly at such a transformational time,” said Dr. Jain. “I am impressed with the company’s successful execution to date and look forward to supporting its future achievements.”\nDr Jain previously served as Chief Medical officer ofImmunovant, Inc.and prior to that Senior Vice President and Chief Medical Officer ofAkebia Therapeutics, Inc.Before joining Akebia, Dr. Jain was Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc., and prior to that served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa®and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others.\nBefore Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle (acquired by Pharmacia and subsequently Pfizer). Earlier in her career, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.\nDr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.\nAbout ChemoCentryx\nChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.","news_type":1,"symbols_score_info":{"CCXI":0.9}},"isVote":1,"tweetType":1,"viewCount":564,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/826049298"}
精彩评论